• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    PACS Group Announces Appointment of Evelyn Dilsaver to Serve as Independent Board Director

    5/13/24 7:31:00 PM ET
    $HQY
    $QDEL
    $TPX
    Business Services
    Consumer Discretionary
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care
    Get the next $HQY alert in real time by email

    PACS Group, Inc. (NYSE:PACS) ("PACS" or the "Company") announced today that Evelyn Dilsaver has been appointed to serve as a member of its Board of Directors. "We're thrilled to have Evelyn join our board," said Jason Murray, PACS Chairman and CEO. "She has great experience as an accounting and finance professional, not to mention her work on the boards of several other public companies. She'll bring added perspective and expertise to the board as we work to guide PACS going forward."

    "I'm excited to join the PACS Board and assist the company in continuing its mission to provide quality skilled nursing care. I look forward to great things ahead for the company," added Ms. Dilsaver.

    Ms. Dilsaver also serves on the boards of directors of Tempur Sealy International (NYSE:TPX), HealthEquity, Inc. (NASDAQ:HQY) and QuidelOrtho (NASDAQ:QDEL). Ms. Dilsaver was President and Chief Executive Officer of Charles Schwab Investment Management from July 2004 until September 2007. Prior to that, she held various senior management positions with The Charles Schwab Corporation. Ms. Dilsaver is a certified public accountant and holds a B.S. degree in accounting from California State University-Hayward.

    Ms. Dilsaver is an independent director under applicable NYSE and SEC rules. Her appointment now makes the PACS Board of Directors majority independent. Ms. Dilsaver's committee appointments will be considered at a later date.

    About PACS Group

    PACS Group, Inc. is a holding company investing in post-acute healthcare facilities, professionals, and ancillary services. Founded in 2013, PACS Group is one of the largest post-acute platforms in the United States. Its independent subsidiaries operate over 200 post-acute care facilities across nine states serving over 20,000 patients daily.

    View source version on businesswire.com: https://www.businesswire.com/news/home/20240513694766/en/

    Get the next $HQY alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $HQY
    $QDEL
    $TPX

    CompanyDatePrice TargetRatingAnalyst
    QuidelOrtho Corporation
    $QDEL
    5/8/2025$44.00Hold → Buy
    Jefferies
    HealthEquity Inc.
    $HQY
    3/25/2025$120.00 → $115.00Outperform → Strong Buy
    Raymond James
    Tempur Sealy International Inc.
    $TPX
    2/5/2025Mkt Perform → Outperform
    William Blair
    Tempur Sealy International Inc.
    $TPX
    2/3/2025$67.00 → $80.00Neutral → Outperform
    Wedbush
    QuidelOrtho Corporation
    $QDEL
    12/11/2024$44.00 → $50.00Neutral → Buy
    Citigroup
    QuidelOrtho Corporation
    $QDEL
    12/10/2024$43.00Hold
    Jefferies
    HealthEquity Inc.
    $HQY
    12/4/2024$126.00Outperform
    Mizuho
    HealthEquity Inc.
    $HQY
    11/15/2024$108.00Neutral
    Goldman
    More analyst ratings

    $HQY
    $QDEL
    $TPX
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • QuidelOrtho Reports First Quarter 2025 Financial Results

      ― Total revenue of $693 million, growth of 5% as reported and 6% in constant currency, excluding COVID-19 and Donor Screening ― ― Strong execution on cost-savings initiatives driving improved margins and profitability ― ― Company maintains full-year 2025 financial guidance ― First Quarter 2025 Results (all comparisons are to the prior year period) Total revenue was $693 million, as reported Non-respiratory revenue was $573 million, which was flat to the prior year period as reported and an increase of 2% in constant currency Labs revenue grew 5% as reported and 7% in constant currency Donor Screening revenue declined by 62% as the Company continues to wind down the U.S. portion of

      5/7/25 4:05:00 PM ET
      $QDEL
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care
    • USA Today Names HealthEquity to its Top 25 Workplaces

      DRAPER, Utah, April 29, 2025 (GLOBE NEWSWIRE) -- HealthEquity, Inc. (NASDAQ:HQY) ("HealthEquity"), the nation's largest health savings account (HSA) administrator, today announced it has been named a USA Today Top Workplace for 2025, ranking 23rd nationwide for companies with more than 2,500 employees. This is HealthEquity's fourth consecutive year on the coveted list, and it is the only company from the healthcare benefits industry to be ranked in the Top 25. "This award is a testament to our incredible teammates who show up every day—wherever they are—with purpose, passion, and care for one another. They've proven that a thriving culture isn't bound by office walls. It's built through t

      4/29/25 9:00:00 AM ET
      $HQY
      Business Services
      Consumer Discretionary
    • QuidelOrtho to Report First Quarter 2025 Financial Results

      QuidelOrtho Corporation (NASDAQ:QDEL) (the "Company") or ("QuidelOrtho"), a global provider of innovative in-vitro diagnostic technologies designed for point-of-care settings, clinical labs and transfusion medicine, announced today that it will report its financial results for its first quarter 2025 ended March 30, 2025, after the market close on Wednesday, May 7, 2025. Following the release of financial results, QuidelOrtho will hold a conference call beginning at 2:00 p.m. PT / 5:00 p.m. ET to discuss its financial results. Interested parties can access the call from the "Events & Presentations" section of the "Investor Relations" page of the Company's website at https://ir.quidelortho.c

      4/23/25 4:30:00 PM ET
      $QDEL
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care

    $HQY
    $QDEL
    $TPX
    SEC Filings

    See more
    • QuidelOrtho Corporation filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

      8-K - QuidelOrtho Corp (0001906324) (Filer)

      5/7/25 4:07:42 PM ET
      $QDEL
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care
    • HealthEquity Inc. filed SEC Form 8-K: Leadership Update, Financial Statements and Exhibits

      8-K - HEALTHEQUITY, INC. (0001428336) (Filer)

      4/28/25 4:01:38 PM ET
      $HQY
      Business Services
      Consumer Discretionary
    • SEC Form 144 filed by HealthEquity Inc.

      144 - HEALTHEQUITY, INC. (0001428336) (Subject)

      4/10/25 4:55:06 PM ET
      $HQY
      Business Services
      Consumer Discretionary

    $HQY
    $QDEL
    $TPX
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • QuidelOrtho upgraded by Jefferies with a new price target

      Jefferies upgraded QuidelOrtho from Hold to Buy and set a new price target of $44.00

      5/8/25 9:44:58 AM ET
      $QDEL
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care
    • HealthEquity upgraded by Raymond James with a new price target

      Raymond James upgraded HealthEquity from Outperform to Strong Buy and set a new price target of $115.00 from $120.00 previously

      3/25/25 8:22:31 AM ET
      $HQY
      Business Services
      Consumer Discretionary
    • Tempur Sealy Int'l upgraded by William Blair

      William Blair upgraded Tempur Sealy Int'l from Mkt Perform to Outperform

      2/5/25 8:03:48 AM ET
      $TPX
      Home Furnishings
      Consumer Discretionary

    $HQY
    $QDEL
    $TPX
    Financials

    Live finance-specific insights

    See more
    • QuidelOrtho Reports First Quarter 2025 Financial Results

      ― Total revenue of $693 million, growth of 5% as reported and 6% in constant currency, excluding COVID-19 and Donor Screening ― ― Strong execution on cost-savings initiatives driving improved margins and profitability ― ― Company maintains full-year 2025 financial guidance ― First Quarter 2025 Results (all comparisons are to the prior year period) Total revenue was $693 million, as reported Non-respiratory revenue was $573 million, which was flat to the prior year period as reported and an increase of 2% in constant currency Labs revenue grew 5% as reported and 7% in constant currency Donor Screening revenue declined by 62% as the Company continues to wind down the U.S. portion of

      5/7/25 4:05:00 PM ET
      $QDEL
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care
    • QuidelOrtho to Report First Quarter 2025 Financial Results

      QuidelOrtho Corporation (NASDAQ:QDEL) (the "Company") or ("QuidelOrtho"), a global provider of innovative in-vitro diagnostic technologies designed for point-of-care settings, clinical labs and transfusion medicine, announced today that it will report its financial results for its first quarter 2025 ended March 30, 2025, after the market close on Wednesday, May 7, 2025. Following the release of financial results, QuidelOrtho will hold a conference call beginning at 2:00 p.m. PT / 5:00 p.m. ET to discuss its financial results. Interested parties can access the call from the "Events & Presentations" section of the "Investor Relations" page of the Company's website at https://ir.quidelortho.c

      4/23/25 4:30:00 PM ET
      $QDEL
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care
    • HealthEquity Reports Fiscal Year and Fourth Quarter Ended January 31, 2025 Financial Results

      Highlights of the fiscal year include: Revenue of $1.20 billion, an increase of 20% compared to $999.6 million in FY24.Net income of $96.7 million, an increase of 74% compared to $55.7 million in FY24, with non-GAAP net income of $277.3 million, an increase of 42% compared to $195.5 million in FY24.Net income per diluted share of $1.09, an increase of 70% compared to $0.64 in FY24, with non-GAAP net income per diluted share of $3.12, an increase of 39% compared to $2.25 in FY24.Adjusted EBITDA of $471.8 million, an increase of 28% compared to $369.2 million in FY24.9.9 million HSAs, an increase of 14% compared to FY24.Total HSA Assets of $32.1 billion, an increase of 27% compared to F

      3/18/25 4:01:00 PM ET
      $HQY
      Business Services
      Consumer Discretionary

    $HQY
    $QDEL
    $TPX
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • President and CEO Blaser Brian J. bought $249,878 worth of shares (6,033 units at $41.42) (SEC Form 4)

      4 - QuidelOrtho Corp (0001906324) (Issuer)

      12/13/24 4:12:57 PM ET
      $QDEL
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care
    • Busky Joseph M bought $99,663 worth of shares (2,150 units at $46.35) (SEC Form 4)

      4 - QuidelOrtho Corp (0001906324) (Issuer)

      2/26/24 6:48:23 PM ET
      $QDEL
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care

    $HQY
    $QDEL
    $TPX
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Chief Operations Officer Mclellan Philip D. was granted 1,945 shares and covered exercise/tax liability with 696 shares, increasing direct ownership by 14% to 10,237 units (SEC Form 4)

      4 - QuidelOrtho Corp (0001906324) (Issuer)

      4/29/25 4:09:19 PM ET
      $QDEL
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care
    • Chief Operations Officer Mclellan Philip D. covered exercise/tax liability with 1,159 shares and was granted 3,237 shares, increasing direct ownership by 30% to 8,988 units (SEC Form 4)

      4 - QuidelOrtho Corp (0001906324) (Issuer)

      4/24/25 4:03:44 PM ET
      $QDEL
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care
    • SEC Form 4 filed by Chief Legal Officer Hodges Michelle A

      4 - QuidelOrtho Corp (0001906324) (Issuer)

      4/22/25 4:03:40 PM ET
      $QDEL
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care

    $HQY
    $QDEL
    $TPX
    Leadership Updates

    Live Leadership Updates

    See more
    • HealthEquity Reports Year-End Sales Metrics

      DRAPER, Utah, Feb. 18, 2025 (GLOBE NEWSWIRE) -- HealthEquity, Inc. (NASDAQ:HQY) ("HealthEquity" or the "Company"), the nation's largest health savings account ("HSA") custodian, today announced its HSAs, HSA Assets and Total Accounts as of its fiscal year ended January 31, 2025. The Company also affirmed its guidance for fiscal 2025 and 2026, provided an updated HSA cash repricing schedule, and announced upcoming events and presentations. The total number of HSAs as of January 31, 2025 was 9.9 million, an increase of 14%, from 8.7 million as of January 31, 2024. The Company closed its fiscal year 2025 with 17.0 million Total Accounts, an increase of 9%, from 15.7 million as of January 31,

      2/18/25 4:01:00 PM ET
      $HQY
      Business Services
      Consumer Discretionary
    • HealthEquity Announces Record Year-End HSA Sales Outlook, Presentation at J.P. Morgan Healthcare Conference

      DRAPER, Utah, Jan. 13, 2025 (GLOBE NEWSWIRE) -- HealthEquity, Inc. (NASDAQ:HQY) ("HealthEquity" or the "Company"), the nation's largest health savings account ("HSA") custodian, today announced estimates of HSAs, HSA Assets and Total Accounts for its fiscal year ending January 31, 2025, reflecting a strong sales year with record New HSAs from Sales and strong custodial HSA Asset growth. Estimated HSAs to be approximately 9.8 million by January 31, 2025, up from 8.7 million a year earlier.Estimated HSA Assets to be approximately $31 billion, up from $25.2 billion at the end of fiscal year 2024, with approximately $17 billion of HSA Cash. Invested balances included in the estimated assets a

      1/13/25 9:01:00 AM ET
      $HQY
      Business Services
      Consumer Discretionary
    • QuidelOrtho Announces Appointment of Two Independent Directors to its Board

      Veteran Healthcare CEOs John R. Chiminski and R. Scott Huennekens Bring Deep Industry Experience, Operational Expertise and Financial Acumen to the QuidelOrtho Board QuidelOrtho Corporation (NASDAQ:QDEL) (the "Company" or "QuidelOrtho"), a global provider of innovative in vitro diagnostic technologies designed for point-of-care settings, clinical labs and transfusion medicine, today announced the appointments of John R. Chiminski and R. Scott Huennekens to its board of directors (the "Board"), effective December 6, 2024. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20241210769572/en/R. Scott Huennekens (Photo: Business Wire) T

      12/10/24 7:00:00 AM ET
      $CTLT
      $HYPR
      $NVST
      $QDEL
      Biotechnology: Pharmaceutical Preparations
      Health Care
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Medical/Dental Instruments

    $HQY
    $QDEL
    $TPX
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by QuidelOrtho Corporation

      SC 13G/A - QuidelOrtho Corp (0001906324) (Subject)

      12/6/24 10:11:24 AM ET
      $QDEL
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care
    • Amendment: SEC Form SC 13D/A filed by QuidelOrtho Corporation

      SC 13D/A - QuidelOrtho Corp (0001906324) (Subject)

      11/21/24 5:10:19 PM ET
      $QDEL
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care
    • Amendment: SEC Form SC 13G/A filed by QuidelOrtho Corporation

      SC 13G/A - QuidelOrtho Corp (0001906324) (Subject)

      11/14/24 1:28:35 PM ET
      $QDEL
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care